4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Innate Pharma S.A. (IPHA) operates in the Biotechnology industry and is headquartered in Marseille, France with about 164 employees. Its market capitalization is roughly $232 million. In the fiscal year ended 2025-12-31, IPHA reported €3M in revenue and (€49M) in net income.
Innate Pharma S.A. operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally.
Interactive charts & full statements → Open the IPHA valuation workbench →
| Income statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Total Revenue | €3M | €13M | €52M | €50M |
| Operating Income (EBIT) | (€53M) | (€52M) | (€13M) | (€16M) |
| Net Income | (€49M) | (€50M) | (€8M) | (€58M) |
EUR; €M / €B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Cash flow | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Dividends Paid | — | — | €0M | €0M | €0M |
EUR; €M / €B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Assets | €63M | €111M | €175M | €199M | — |
| Total Liabilities | €84M | €102M | €123M | €145M | — |
EUR; €M / €B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive IPHA viewer.
About TickerBase · Data methodology & sources · Privacy · Terms